Abstract

  Myasthenia gravis is a long-term neuromuscular disease that leads to varying degrees of skeletal weakness. The most affected muscles are those of the face and eyes which results in drooping eyelids, double vision, trouble walking and trouble talking. Those affected often develop a thymoma. Some of the drugs used in the treatment are Pyridostigmine, Azathioprine, Mycophenolate mofetil, Neostigmine, Ephedrine. A brief review of the analytical methods developed for the estimation of these drugs was discussed in the present study.

Keywords: Myasthenia Gravis; Azathioprine; Mycophenolate Mofetil

References

1. Scherer K., et al. “Does this patient have myasthenia gravis?”. The Journal of the American Medical Association 293.15 (2005): 1906-1914.
2. Singer W., et al. “Acetylcholinesterase inhibition: a novel approach in the treatment of neurogenic orthostatic hypotension”. Journal of Neurology, Neurosurgery, and Psychiatry 74.9 (2003): 1294-1298.
3. Woodroffe R., et al. “Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study”. Health Technology Assessment 9.21 (2005): 1-179.
4. Picard N., et al. “Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5”. Therapeutic Drug Monitoring 26.6 (2004): 600-608.
5. Saito S., et al. “Cholinesterase inhibitors induce growth cone collapse and inhibit neurite extension in primary cultured chick neurons”. Neurotoxicology and Teratology 20.4 (1998): 411-419.
6. Cherstniakova SA., et al. “Rapid determination of N, N-diethyl-m-Toluamide and Permethrin in human plasma by gas chromatography-mass spectrometry and Pyridostigmine bromide by high-performance liquid chromatography”. Journal of Analytical Toxicology 30.1 (2006): 21-26.
7. Chan K., et al. “A quantitative Gas-liquid chromatographic method for the determination of Neostigmine and Pyridostigmine in human plasma”. Journal of Chromatography A 120.2 (1976): 349-358.
8. Gowda KV., et al. “Analysis of Pyridostigmine bromide in human plasma and its application in bioequivalence studies”. Journal of Liquid Chromatography and Related Technologies 30.17 (2007): 2605-2615.
9. Abu-Qare AW and Abou-Donia MB. “A validated HPLC method for the determination of pyridostigmine bromide, acetaminophen, acetylsalicylic acid and caffeine in rat plasma and urine”. Journal of Pharmaceutical and Biomedical Analysis 26.5-6 (2001): 939-947.
10. Karthik A., et al. “Development and validation of a HPLC method for quantification of rivastigmine in rat urine and identification of a novel metabolite in urine by LC‐MS/MS”. Biomedical chromatography 25.3 (2011): 353-361.
11. Abu-Qare W and Abou-Donia B. “Simultaneous analysis of sarin, Pyridostigmine bromide and their metabolites in rat plasma and urine using HPLC”. Chromatographia 53.5-6 (2001): 251-255.
12. Yakatan GJ and Tien JY. “Quantitation of Pyridostigmine in plasma using high-performance liquid chromatography”. Journal of Chromatography 164.3 (1979): 399- 403.
13. Aqel W Abu-Qare and Mohamed B Abou-Donia. “Simultaneous determination of Pyridostigmine bromide, N, N-diethyl-m-toluamide, permethrin, and their metabolites in rat plasma and urine by high-performance liquid chromatography”. Journal of Chromatography B: Biomedical Sciences and Applications 749.2 (2000): 171-178.
14. Needham SR., et al. “Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of Pyridostigmine bromide from guinea pig plasma”. Journal of Chromatography B 796.2 (2003): 347-354.
15. Souza AC., et al. “Development and characterization of multilamellar liposomes containing Pyridostigmine”. Pharmaceutical Development and Technology 19.4 (2013): 454-459.
16. Nouruddin Wageih Ali., et al. “Development and Validation of a Stability-Indicating High-Performance Thin-layer chromatographic method for determination of Pyridostigmine bromide in the presence of its alkaline-induced degradation product”. JPC - Journal of Planar Chromatography - Modern TLC 28.4 (2015): 316-322.
17. Tatiana Tatit Fazio., “Quantitative determination and sampling of Azathioprine residues for cleaning validation in production area”. Journal of Pharmaceutical and Biomedical Analysis 43.4 (2007): 1495-1498.
18. Dervieux T and Boulieu R. “Simultaneous determination of 6-Thioguanine and methyl 6-mercaptopurine nucleotides of Azathioprine in red blood cells by HPLC”. Clinical Chemistry 44.3 (1998): 551-555.
19. Bhaskar M., et al. “RP-HPLC method development for the determination of Azathioprine in bulk drug and pharmaceutical dosage forms”. International Journal of Chem Tech Research 2 (2010): 1176-1179.
20. Ravisankar P., et al. “Development and validation of rapid RP- HPLC method for the determination of Azathioprine in bulk and pharmaceutical dosage form”. Scholars Research Library 7.3 (2015): 85-95.
21. Davadra PM., et al. “A validated UPLC method for the determination of process-related impurities in Azathioprine bulk drug”. 3 (2011): 198-204.
22. Kulkarni S., et al. “A validated high-performance thin-layer chromatographic method for the determination of Azathioprine from pharmaceutical formulation”. JPC - Journal of Planar Chromatography - Modern TLC. 27.2 (2014): 120-123.
23. Maria Shipkova., et al. “Identification of glucoside and carboxyl-linked glucuronideconjugates of mycophenolic acid in plasma of transplant recipients treated with Mycophenolate mofetil”. British Journal of Pharmacy 126.5 (2009): 1075-1082.
24. Irene Tsina., et al “High-performance liquid chromatographic method for the determination of Mycophenolate mofetil in human plasma”. Journal of Chromatography B: Biomedical Sciences and Applications 681.2 (1996): 347-353.
25. K Na-Bangchang., et al. “Simple and sensitive high-performance liquid chromatographic method for the determination of Mycophenolic acid in plasma”. Journal of Chromatography B: Biomedical Sciences and Applications 738.1(2000): 169-173.
26. Hossein Danafar., et al. “Simple and sensitive high-performance liquid chromatography (HPLC) method with UV detection for Mycophenolic acid assay in human plasma. Application to a bioequivalence study”. Advanced Pharmaceutical Bulletin 5.4 (2015): 563-568.
27. Protic A., et al. “Development of liquid chromatographic method for simultaneous determination of Mycophenolate mofetil and its degradation product mycophenolic acid in dosage form”. Journal of Chromatographic Science 47.2 (2009): 149-155.
28. Ljiljana Zivanovic., et al. “Multi criteria optimization methodology in development of HPLC separation of Mycophenolic acid and Mycophenolic acid glucuronide in human urine and plasma”. Journal of Pharmaceutical and Biomedical Analysis 50.4 (2009): 640-648.
29. Figurski., et al. “High-performance liquid chromatography-mass spectroscopy/mass spectroscopy method for simultaneous quantification of total or free fraction of Mycophenolic acid and its glucuronide metabolites”. 31.6 (2009): 717-726.
30. Chirag G., et al. “High-performance liquid chromatography method for the determination of Mycophenolic acid and its acyl and phenol glucuronide metabolites in human plasma”. Therapeutic Drug Monitoring 28.1 (2006): 116-122.
31. S Verma., et al. “Spectrophotometric methods for the estimation of Mycophenolate mofetil”. Journal of Applied Spectroscopy 76 (2009): 876-882
32. Xavier Delavenne., “UPLC MS/MS method for quantification of Mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study”. Clinica Chimica Acta 412.1-2 (2011): 59-65.
33. Streit F., et al. “Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total Mycophenolic acid”. Clinical Chemistry 50.1 (2004) 152-159.
34. Bing Shen., et al. “Determination of total, free and saliva Mycophenolic acid with a LC-MS/MS method: Application to pharmacokinetic study in healthy volunteers and renal transplant patients”. Journal of Pharmaceutical and Biomedical Analysis 50.3 (2009): 515-521.
35. Kathirvel S., et al. “Development and validation of HPTLC method for the determination of Mycophenolate mofetil in bulk and pharmaceutical formulation”. Pharmaceutical Methods 3.2 (2012): 90-93.
36. Lena Schönberg., et al. “New screening method for basic compounds in urine by on-line extraction-high-performance liquid chromatography with photodiode-array detection”. Journal of Chromatography A 1134.1-2 (2006): 177-185.
37. Ying Shi., et al. “Development of a liquid chromatography tandem mass spectrometry method for simultaneous determination of eight adulterants in slimming functional foods”. Journal of Chromatography A 1218.42 (2011): 7655-7662.
38. Chunhua Ma., et al. “Pharmacokinetic properties of Ephedrine, Amygdalin and Glycyrrhizic acid after oral gavage of San-Ao-decoction in beagle dogs using a UPLC-MS method”. Analytical Methods 5.8 (2013): 2119-2125.
39. Deventer K., et al. “Development and validation of an LC-MS/MS method for the quantification of Ephedrines in urine”. Journal of Chromatography B 877.4 (2009): 369-374.
40. Ziyan Hu., et al. “Simultaneous determination of Codeine, Ephedrine, Guaiphenesin and Chlorpheniramine in beagle dog plasma using high performance liquid chromatography coupled with tandem mass spectrometric detection”. Journal of Chromatography B 879.32 (2011): 3937-3942.
41. Zheng Zhijie., et al. “Pharmacokinetic determination of Ephedrine in Herba Ephedrae and Wu Tou Tang decoctions in rats using ultra performance liquid chromatography tandem mass spectrometry. The fate of foreign compounds in biological systems”. Xenobiotica 42.8 (2012): 775-783.
42. Sorensen LK., et al. “Determination of cathinones and related Ephedrines in forensic whole-blood samples by liquid-chromatography-electrospray tandem mass spectrometry”. Journal of Chromatography B 879.11-12 (2011): 727-736.
43. Shuang Ren., et al. “Simultaneous determination of Ephedrine and Chlorpheniramine in human plasma by a highly sensitive liquid chromatography-tandem mass spectrometric method”. 41.2 (2006): 188-192.
44. Cooper SD., et al. “Determination of L-Ephedrine, Pseudoephedrine, and Caffeine in rat plasma by liquid chromatography-tandem mass spectrometry”. Journal of Analytical Toxicology 35.6 (2011): 341-348.
45. Barbora Tircova., et al. “HILIC-MS/MS method for analysis of Ephedrine in internet-available drugs”. Chromatographia 80.4 (2017): 523-528.
46. Kolmonen M., et al. “A general screening method for doping agents in human urine by solid phase extraction and liquid chromatography/time-of-flight mass spectrometry”. Analytica Chimica Acta 585.1 (2007): 94-102.
47. Ximei Wu., et al. “Simultaneous determination of six alkaloids in blood and urine using a Hydrophilic interaction liquid chromatography method coupled with electrospray ionization tandem mass spectrometry”. Analytical and Bioanalytical Chemistry 398 (2010): 1319-1327.

Citation

Citation: Raghu Raj Naik and Choppala Asha Deepti. “Analytical Methods for the Determination of Drugs Used in Myasthenia Gravis - A Review". Acta Scientific Pharmaceutical Sciences 4.2 (2020): 98-103.